

Supplementary Table 1. Patient information

Ref.	Age	Gender	Primary diagnosis	Stage at treatment	Metastasis at inclusion	Braf Mutation	Previous treatment
A	79	Female	Cutaneous Melanoma	IVMb	Kidney, Lymph nodes	negative	Temozolomide Carboplatin Paclitaxel
B	25	Male	Cutaneous Melanoma	IVMb	Lymph nodes	positive	Vemurafenib
C	67	Female	Cutaneous Melanoma	III	Lymph nodes	negative	Surgery
D	79	Male	Cutaneous Melanoma	IVMb	Lymph nodes	positive	Surgery
E	85	Female	Cutaneous Melanoma	III	In transit	ND	Surgery

ND: Not determined

Supplementary Table 2. Antibodies used in flow cytometry

Marker	Conjugate	Clone
Arg ¹	PO*	6G3
CCR7 ²	PE	150503
CD3 ²	FITC	UCHT1
CD3 ³	PerCP-Cy5.5	SK7
CD3 ³	PE-Cy7	UCHT1
CD4 ⁴	PE-TR	S3.5
CD8 ⁴	PE-A1f610	3B5
CD8 ³	APC-Cy7	SK1
CD11b ²	APC-Cy7	ICRF44
CD11c ⁵	FITC	KB90
CD14 ³	PB	M5E2
CD14 ³	PerCP-Cy5.5	M5E2
CD15 ²	PE-Cy7	HI98
CD19 ²	PerCP-Cy5.5	HIB19
CD25 ³	PB	BC96
CD28 ³	PerCP-Cy5.5	CD28.2
CD33 ³	APC	WM53
CD45RA ³	APC	HI100
CD69 ³	APC-Cy7	FN50
CD127 ³	A1f647	A019D5
FoxP3 ⁶	FITC	PCH101
HLA-DR ³	PE	L243
PD1 ³	PB	EH12.2H7
PD1L ²	PE-Cy7	MIH1

* conjugated with Pacific Orange Labeling Kit (Invitrogen, Carlsbad, CA)

¹Hycult Biotech (Plymouth Meeting, PA), ²BD Biosciences (San Jose, CA), ³BioLegend (San Diego, CA), ⁴Invitrogen (Carlsbad, CA), ⁵DakoCytomation (Glostrup, DK), ⁶eBioscience (San Diego, CA).